89Zr-Labeled Anti-PD-L1 Antibody PET Monitors Gemcitabine Therapy-Induced Modulation of Tumor PD-L1 Expression
暂无分享,去创建一个
Kyung-Han Lee | Kyung-Ho Jung | Jin Hee Lee | S. Moon | Y. Cho | J. Park
[1] Tao Yu,et al. Application of molecular imaging technology in tumor immunotherapy. , 2020, Cellular immunology.
[2] C. H. Nielsen,et al. Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody , 2019, European Journal of Nuclear Medicine and Molecular Imaging.
[3] Kyung-Han Lee,et al. Troglitazone exerts metabolic and antitumor effects on T47D breast cancer cells by suppressing mitochondrial pyruvate availability. , 2019, Oncology reports.
[4] J. Bussink,et al. Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer , 2019, EJNMMI Radiopharmacy and Chemistry.
[5] E. Giovannetti,et al. PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition , 2019, Cancers.
[6] B. Brodská,et al. High PD-L1 Expression Predicts for Worse Outcome of Leukemia Patients with Concomitant NPM1 and FLT3 Mutations , 2019, International journal of molecular sciences.
[7] S. Perkins,et al. Prognostic Significance of the Dynamic Change of Programmed Death-ligand 1 Expression in Patients with Multiple Myeloma , 2019, Cureus.
[8] Zhaoming Li,et al. Predictive biomarkers for PD-1 and PD-L1 immune checkpoint blockade therapy. , 2019, Immunotherapy.
[9] I. C. Kok,et al. 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade in cancer , 2018, Nature Medicine.
[10] R. Stahel,et al. Gemcitabine Synergizes with Immune Checkpoint Inhibitors and Overcomes Resistance in a Preclinical Model and Mesothelioma Patients , 2018, Clinical Cancer Research.
[11] T. Schumacher,et al. Regulation and Function of the PD-L1 Checkpoint. , 2018, Immunity.
[12] Y. Naito,et al. The JAK/STAT pathway is involved in the upregulation of PD-L1 expression in pancreatic cancer cell lines. , 2017, Oncology reports.
[13] A. Ribas,et al. Combination cancer immunotherapies tailored to the tumour microenvironment , 2016, Nature Reviews Clinical Oncology.
[14] P. Millner,et al. Considerations in producing preferentially reduced half-antibody fragments. , 2016, Journal of immunological methods.
[15] S. Murphy,et al. Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor-κB to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer. , 2015, Cancer research.
[16] H. Ishwaran,et al. Radiation and Dual Checkpoint Blockade Activates Non-Redundant Immune Mechanisms in Cancer , 2015, Nature.
[17] Shohei Koyama,et al. Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression. , 2014, Cancer cell.
[18] Antoni Ribas,et al. Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma , 2014, Clinical Cancer Research.
[19] I. Endo,et al. Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer , 2014, Clinical and Translational Oncology.
[20] Jun Hu,et al. PTEN Loss Increases PD-L1 Protein Expression and Affects the Correlation between PD-L1 Expression and Clinical Parameters in Colorectal Cancer , 2013, PloS one.
[21] David C. Smith,et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.
[22] G. Freeman,et al. The Programmed Death-1 Ligand 1:B7-1 Pathway Restrains Diabetogenic Effector T Cells In Vivo , 2011, The Journal of Immunology.
[23] C. Liu,et al. Cisplatin induces programmed death-1-ligand 1(PD-L1) over-expression in hepatoma H22 cells via Erk /MAPK signaling pathway. , 2010, Cellular and molecular biology.
[24] Judith E. Flores,et al. Site-specifically 89Zr-labeled monoclonal antibodies for ImmunoPET. , 2010, Nuclear medicine and biology.
[25] Tae Woo Kim,et al. Activation of Akt as a mechanism for tumor immune evasion. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] G. Freeman,et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. , 2007, Immunity.
[27] S. Albelda,et al. Gemcitabine has significant immunomodulatory activity in murine tumor models independent of its cytotoxic effects , 2007, Cancer biology & therapy.
[28] Haidong Dong,et al. Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion , 2002, Nature Medicine.
[29] R. Herbst,et al. Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non-Small-Cell Lung Cancer. , 2016, JAMA oncology.
[30] P. Mischel,et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma , 2007, Nature Medicine.